Alexander Shneider, founder and CEO of CureLab Oncology, Inc. shared a post on LinkedIn:
“We are honored to see our recent clinical data featured in EMJ Oncology. For patients with platinum‑resistant ovarian cancer – one of the most challenging diagnoses in oncology – these findings point toward what may become a meaningful paradigm shift.
Clinical Highlights:
- Doubling of Median Survival: 13 → 25+ months in this study
- Zero Added Toxicity: A rare safety profile that supports the body’s biology rather than intensifying chemotherapy
- A New Class of Therapy: Reinforcing Elenagen’s unique role in modulating chronic inflammation and reshaping the tumor microenvironment
As we move toward our US/Global Phase II/III trials, this external validation underscores the life‑saving potential of our platform.
The Path Forward:
We hope this recognition – alongside dozens of recent features in English, Spanish, and Portuguese – encourages future partners and investors to engage with the speed required to bring this potential breakthrough to clinicians and patients.”
Read the full feature
Other articles about Ovarian Cancer on OncoDaily.